A.        
Patient groups CD19+PPS14+  % Day 0 CD19+PPS14+  % Day7 CD19+PPS23F+  % Day 0 CD19+PPS23F+ % Day7
Group A (CD4>200) 1.37 ± 0.29   2.87 ± 0.30*** 1.29 ± 0.23 2.76 ± 0.23***
Group B  (CD4<200) 0.69 ± 0.11 2.95 ± 0.74** 0.62 ± 0.11 2.22 ± 0.41**
B.        
Patient groups CD19+PPS14+ (cells/ml)Day 0 CD19+PPS14+ (cells/ml) Day 7 CD19+PPS23F+  (cells/ml) Day 0 CD19+PPS23F+ (cells/ml) Day 7
Group A (CD4>200) 2006 ± 565 3696 ± 413** 1374 ± 202 3809 ± 441***
Group B  (CD4<200) 1036 ± 280 3768 ± 758** 1038 ± 280 3330 ± 628**
Data are mean ± standard error of the mean. * indicates significant rise in the post vaccination (day7) levels compared to pre-vaccination (day 0) within a group. Cell counts of specific cell population in donor groups are reported as the average value of = [(percentage of specific cell population) * total lymphocytes/ml] for that group. Pre to post vaccination changes in a single group were compared using paired t-test and between groups were compared using analysis of co-variance (ANCOVA).*p<0.05, **p<0.01, ***p<0.001.
Table 3: PPS-selected CD19+ B cell percentages (%) and absolute numbers (cells/ml) in long term HAART cohorts pre and 7 days post PPV23 revaccination.
Goto home»